234 CHURCH STREET, NEW HAVEN, CT
CFO Jonathan Lieber to Transition to Part-Time Status at Rallybio
Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement, Investor Presentation
News, Reorganization Plan
Departure of Chief Medical Officer Steven Ryder at Rallybio Corporation
Investor Presentation
Rallybio Corporation Files Certificate of Amendment for Reverse Stock Split
Reports Third Quarter 2025 Financial Results and Provides Business Updates
News
Q2
Q1
FY 2025
Q3
FY 2024
S-4/A
S-4
Prospectus Filed Pursuant to Rule 425
RW
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence
SEC Staff Correspondence